{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:31:19Z","timestamp":1790346679471,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472820"],"award-info":[{"award-number":["81472820"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700037"],"award-info":[{"award-number":["81700037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773255"],"award-info":[{"award-number":["81773255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972888"],"award-info":[{"award-number":["81972888"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013058","name":"Jiangsu Provincial Key Research and Development Program","doi-asserted-by":"publisher","award":["BE2018701"],"award-info":[{"award-number":["BE2018701"]}],"id":[{"id":"10.13039\/501100013058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncolytics"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.omto.2020.11.001","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T21:13:35Z","timestamp":1605561215000},"page":"12-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance"],"prefix":"10.1016","volume":"20","author":[{"given":"Hailin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2020.11.001_bib1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00109-016-1453-9","article-title":"Oncolytic viruses\u2014immunotherapeutics on the rise","volume":"94","author":"Keller","year":"2016","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"key":"10.1016\/j.omto.2020.11.001_bib2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omto.2020.11.001_bib3","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omto.2020.11.001_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omto.2020.11.001_bib5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s11262-017-1488-1","article-title":"Oncolytic viruses: adenoviruses","volume":"53","author":"Niemann","year":"2017","journal-title":"Virus Genes"},{"key":"10.1016\/j.omto.2020.11.001_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Garcia-Carbonero","year":"2017","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2020.11.001_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","article-title":"A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)","volume":"7","author":"Machiels","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2020.11.001_bib8","doi-asserted-by":"crossref","first-page":"e1532763","DOI":"10.1080\/2162402X.2018.1532763","article-title":"Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model","volume":"8","author":"Kuryk","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omto.2020.11.001_bib9","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/jmv.25229","article-title":"Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5\/3-D24-GM-CSF) in peritoneal mesothelioma mouse model","volume":"90","author":"Kuryk","year":"2018","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.omto.2020.11.001_bib10","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omto.2020.11.001_bib11","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3390\/cells9040798","article-title":"TNFa and IL2 encoding oncolytic adenovirus activates pathogen and danger-associated immunological signaling","volume":"9","author":"Heini\u00f6","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.omto.2020.11.001_bib12","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ymthe.2020.01.003","article-title":"Immune modulation by telomerase-specific oncolytic adenovirus synergistically enhances antitumor efficacy with Anti-PD1 antibody","volume":"28","author":"Kanaya","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.11.001_bib13","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","article-title":"Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T\u00a0cells to control the growth of heterogeneous tumors","volume":"28","author":"Porter","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.11.001_bib14","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ymthe.2019.07.019","article-title":"Recombinant adenovirus expressing a soluble fusion protein PD-1\/CD137L subverts the suppression of CD8+ T\u00a0cells in HCC","volume":"27","author":"Zhang","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.11.001_bib15","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/14712598.2015.1044433","article-title":"Arming oncolytic viruses to leverage antitumor immunity","volume":"15","author":"de Gruijl","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omto.2020.11.001_bib16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omto.2020.11.001_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fonc.2014.00074","article-title":"Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity","volume":"4","author":"Guo","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omto.2020.11.001_bib18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T\u00a0cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omto.2020.11.001_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omto.2020.11.001_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T\u00a0cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omto.2020.11.001_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.omto.2020.02.001","article-title":"NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer","volume":"16","author":"Leung","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2020.11.001_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a key inhibitor of the cancer immunity cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.omto.2020.11.001_bib23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T\u00a0cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2020.11.001_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1084\/jem.20030788","article-title":"Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule","volume":"198","author":"Bottino","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omto.2020.11.001_bib25","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ccell.2014.11.016","article-title":"TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit","volume":"26","author":"Pauken","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2020.11.001_bib26","first-page":"3057","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients. Clin","volume":"22","author":"Kong","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.11.001_bib27","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1038\/s41388-018-0288-y","article-title":"Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option","volume":"37","author":"Stamm","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.omto.2020.11.001_bib28","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omto.2020.11.001_bib29","doi-asserted-by":"crossref","first-page":"e1674605","DOI":"10.1080\/2162402X.2019.1674605","article-title":"Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer","volume":"8","author":"Stamm","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omto.2020.11.001_bib30","doi-asserted-by":"crossref","first-page":"9213","DOI":"10.1128\/JVI.01213-15","article-title":"Patient-specific neutralizing antibody responses to herpes simplex virus are attributed to epitopes on gD, gB, or both and can be type specific","volume":"89","author":"Cairns","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2020.11.001_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-019-1251-7","article-title":"Ivermectin reverses the drug resistance in cancer cells through EGFR\/ERK\/Akt\/NF-\u03baB pathway","volume":"38","author":"Jiang","year":"2019","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.11.001_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cytogfr.2016.07.005","article-title":"The untold story of IFN-\u03b3 in cancer biology","volume":"31","author":"Kursunel","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.omto.2020.11.001_bib33","doi-asserted-by":"crossref","first-page":"14754","DOI":"10.1038\/ncomms14754","article-title":"Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omto.2020.11.001_bib34","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI98047","article-title":"PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy","volume":"128","author":"Zamarin","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"issue":"Suppl 2","key":"10.1016\/j.omto.2020.11.001_bib35","doi-asserted-by":"crossref","first-page":"P337","DOI":"10.1186\/2051-1426-3-S2-P337","article-title":"Potentiation of anti-glioma immunity induced by oncolytic adenovirus Delta-24-RGD through viral expression of immune co-stimulator OX40 ligand","volume":"3","author":"Jiang","year":"2015","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2020.11.001_bib36","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/0008-5472.CAN-11-2788","article-title":"Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer","volume":"72","author":"John","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.11.001_bib37","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-19-0628","article-title":"Intratumoral delivery of a PD-1-blocking scFv encoded in oncolytic HSV-1 promotes antitumor immunity and synergizes with TIGIT blockade","volume":"8","author":"Lin","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omto.2020.11.001_bib38","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1158\/0008-5472.CAN-09-2522","article-title":"Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand","volume":"69","author":"Kim","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.11.001_bib39","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.vaccine.2015.06.087","article-title":"An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression","volume":"34","author":"Ragonnaud","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.omto.2020.11.001_bib40","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.11.001_bib41","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2020.11.001_bib42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omto.2020.11.001_bib43","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omto.2020.11.001_bib44","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1158\/0008-5472.CAN-16-1638","article-title":"Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy","volume":"77","author":"Bartee","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.11.001_bib45","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/mt.2012.252","article-title":"Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response","volume":"21","author":"Shin","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.11.001_bib46","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","article-title":"Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy","volume":"26","author":"Ricca","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.11.001_bib47","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1158\/1078-0432.CCR-14-2009","article-title":"Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy","volume":"21","author":"Rojas","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.11.001_bib48","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.ymthe.2018.07.013","article-title":"Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade","volume":"26","author":"Kowalsky","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.11.001_bib49","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/sj.gt.3302556","article-title":"The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma","volume":"12","author":"Xu","year":"2005","journal-title":"Gene Ther."}],"container-title":["Molecular Therapy Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770520301662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770520301662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:30:39Z","timestamp":1784723439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770520301662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":49,"alternative-id":["S2372770520301662"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2020.11.001","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2020.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}]}}